1. Home
  2. |Insights
  3. |Section 809 Panel Recommends Five Changes to Bid Protests in DoD Procurements

Section 809 Panel Recommends Five Changes to Bid Protests in DoD Procurements

Client Alert | 1 min read | 01.30.19

As previously reported, the Section 809 Panel released the third and final volume of its report on January 15, 2019. Volume 3 contains several recommendations that, if implemented, would materially impact the bid protest process. These recommendations include:

  • Rec. 35 – Institute new procedures for DoD’s acquisition of “readily available” goods and services, replacing current procedures for the acquisition of commercial items. The proposal would eliminate all pre-award protests, as well as post-award protests at GAO and COFC, for procurements of “readily available” items valued at less than $15 million. Agency level challenges would be limited to whether DoD had conducted adequate market research to confirm “readily available” status.
  • Rec. 66 – Establish a “purpose statement” for protests.
  • Rec. 67 – Eliminate follow-on protests at COFC after a GAO protest, and impose a 100-day deadline for the issuance of a decision on protests filed at COFC.
  • Rec. 68 – Limit COFC and GAO protest jurisdiction to procurements greater than $75,000.
  • Rec. 69 – For all required debriefings, provide a redacted Source Selection Decision Document and technical evaluation for the offeror requesting the debriefing.

The full report can be found here.

We will be providing further analysis of these and other issues related to the panel’s final volume on our blog shortly. Stay tuned for updates.


Contacts

Insights

Client Alert | 2 min read | 09.18.25

FDA Announces Intention to Initiate an Aggressive Enforcement Campaign Against Misleading Pharmaceutical Advertising

On September 9, 2025, the U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration (HHS) issued a news release announcing an “aggressive[]” “crackdown” on direct-to-consumer pharmaceutical advertising. This release came on the heels of a Presidential Memorandum President Trump issued the same day directing HHS to “ensure transparency and accuracy in direct-to-consumer prescription drug advertisements,” and the FDA to “take action to enforce legal requirements that advertisements for prescription drugs be truthful and not misleading.”...

View All Insights